title: May vaptans contribute to the treatment of refractory ascites?
authors.forename: Francesco
authors.initials: F
authors.lastname: Salerno
authors.forename: Massimo
authors.initials: M
authors.lastname: Cazzaniga
authors.forename: Silvia
authors.initials: S
authors.lastname: Accordino
mesh_terms: D065092:Antidiuretic Hormone Receptor Antagonists; D001201:Ascites / Q000628:therapy*; D003131:Combined Modality Therapy; D004232:Diuretics / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007010:Hyponatremia / Q000188:drug therapy; D008103:Liver Cirrhosis / Q000150:complications*; D009025:Morpholines / Q000627:therapeutic use*; D019152:Paracentesis; D013141:Spiro Compounds / Q000627:therapeutic use*; D013148:Spironolactone / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D065092:Antidiuretic Hormone Receptor Antagonists; D004232:Diuretics; D009025:Morpholines; D013141:Spiro Compounds; D013148:Spironolactone; C103281:satavaptan